Login to Your Account



Capital Scarcity a Driving Force

Build-to-Buy Requires Early Partnerships, Back-up Plan

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, November 28, 2011

In a time when it's difficult to raise capital through the public markets, licensing deals are necessary to fund programs, and M&A has developed into the go-to exit strategy for private biotechs.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription